Welcome to the international HTA database

Showing [21797 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	Basque Office for Health Technology Assessment (OSTEBA)	[Financing procedures in primary care adequate for resources and efficiency, by means of adjusted clinical groups (ACG)]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[FilmArray® in Acute Respiratory Infections and Sepsis]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2014	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Field evaluation of the initial treatment of STEMI in Quebec's hospitals - phase 2]
2020	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Field evaluation of the implementation of video teleconsultations during the COVID-19 pandemic at the Quebec Heart and Lung Institute]
2013	Andalusian Health Technology Assessment Area (AETSA)	[Fidaxomicin for the treatment of clostridium difficile infection]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fidaxomicin (clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fidanacogene elaparvovec (haemophilia B); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Fibromyalgia and chronic fatigue syndrome: recommendations on diagnosis and treatment]
2010	Committee for New Health Technology Assessment (CNHTA)	[Fiberoptic endoscopic evaluation of swallowing]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fetoscopic laser photocoagulation in twin-twin transfusion syndrome]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fetal neurosonography in suspected central nervous system abnormalities]
2012	Finnish Office for Health Care Technology Assessment (Finohta)	[Fetal intrapartum surveillance - Does STAN improve safety? A meta-analysis]
2016	The Swedish Council on Health Technology Assessment (SBU)	[Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Spectrum Disorders (FASD) – conditions and interventions]
2013	The Regional Health Technology Assessment Centre (HTA-centrum)	[Fertility preservation in girls and young women in whom potentially gonadotoxic treatment is planned or has been performed]
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	[Ferrara corneal ring for treating keratoconus]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fenfluramine (Lennox-Gastaut syndrome, add-on therapy, = 2 years) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fenfluramine (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2010	The Regional Health Technology Assessment Centre (HTA-centrum)	[Fenestrated aortic repair of aortic aneurysm]
2018	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Femoral neck fracture: evaluation of the hospital care process]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fedratinib (myelofibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Federal structures of the prevention of alcohol misuse among children and youths]
2008	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Federal structures and associated behavioural interventions in prevention of cigarette smoking]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2010	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fecal calprotectin: diagnostic marker and treatment assessment in bowel inflammatory disease]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Feasibility and appropriateness of implementing satellite radiotherapy centres equipped with a single linear accelerator]
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Fear of childbirth, depression and anxiety during pregnancy]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[FDG-PET for avoidance of futile direct laryngoscopies under general anaesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapy]
2010	Committee for New Health Technology Assessment (CNHTA)	[FBN1 exon deletion test[MLPA]]
2005	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Fast-track colonic surgery: a health technology assessment]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2012	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fampridine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2006	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Familial hypercholesterolemia: evaluation of genetic screening by DNA microarrays]
2012	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Falls prevention for the elderly]
2012	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Falls prevention for the elderly]
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Falls in patients living in health care facilities (short- and long-term care)]
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Falling in line with the guidelines. Development and pilot testing of an implementation strategy to increase physiotherapists' adherence to evidence-based guidelines for patients with low back pain; a planned, systematic, and theory-based approach]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Fall-safe assist. Portable device for falls prevention]
2011	Health Council of the Netherlands Gezondheidsraad (GR)	[Fair compensation. Consideration of a proposal to give live kidney donors priority for transplants]
2017	Andalusian Health Technology Assessment Area (AETSA)	[Faecal microbiota transplant for recurrent clostridium difficile infection. Up-date]
2011	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fact sheet: Screening for gestational diabetes - rapid report]
2008	Committee for New Health Technology Assessment (CNHTA)	[Facioscapulohumeral muscular dystrophy, D4Z4 analysis, PFGE/Southern Blot]
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Facility planning and infection prevention: sanitary facilities in specialized care rooms and cubicles]
2009	Committee for New Health Technology Assessment (CNHTA)	[F7 gene, mutation[sequencing]]
2009	Committee for New Health Technology Assessment (CNHTA)	[F12 gene, mutation[sequencing]]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ezetimibe for the prevention of cardiovascular events - Rapid report]
2011	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ezetimibe for hypercholesterolaemia]
2008	Committee for New Health Technology Assessment (CNHTA)	[Eyeball brachytherapy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eye controlled speech generating devices]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eye controlled speech generating device]
2009	Committee for New Health Technology Assessment (CNHTA)	[Extremely low temperature cool chamber]
2012	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Extracranial stereotactic body radiotherapy in oligometastasis]
2004	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Extracorporeal shock-wave treatment in orthopedics and rehabilitation. Update]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Extracorporeal shock wave therapy in musculoskeletal disorders]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Extracorporeal shock wave therapy for orthopaedic indications]
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Extracorporeal shock wave therapy (ESWT) for the treatment of delayed union or non-union of fractures]
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Extracorporeal shock wave therapy (ESWT) for heel pain]
2009	Committee for New Health Technology Assessment (CNHTA)	[Extracorporeal photopheresis]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Extracorporeal photopheresis: main indications and implementation parameters]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2009	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Extracorporeal liver support of liver failure by means of Prometheus system]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Extracorporeal High-Intensity Focused Ultrasound (HIFU) in solid tumours]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[External review and validation of methodological instruments for the critical reading and summary of scientific evidence]
2007	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[External manual. Part 1]
2003	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[External evaluation of DACEHTA]
2010	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[External evaluation of cancer care organization and delivery: review of experiences relevant to the cancer team evaluation and designation process in Québec]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2012	Andalusian Health Technology Assessment Area (AETSA)	[Extended neonatal screening for lysosomal diseases by mass spectrometry]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Extended adjuvant endocrine therapy in breast cancer]
2006	Andalusian Health Technology Assessment Area (AETSA)	[Expulsion stage of delivery: comparison of upright versus lying down positions for childbirth, through maternal and foetal outcomes]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploratory examination of the need for revision of the DMP "coronary heart disease"]
2020	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Exploratory evaluation of the relevance, use, and impacts of teleconsultations]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Surgery for varices" - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Decompression for carpal tunnel syndrome" - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Conization of the cervix uteri" - Rapid report]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploration of the topic "Cataract surgery" -Rapid report]
2007	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Expertise on endometriosis]
2020	National Committee for Technology Incorporation (CONITEC)	[Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Expanding thrombolysis in acute ischemic stroke: organizing effective and efficient daily care in The Netherlands]
2024	Basque Office for Health Technology Assessment (OSTEBA)	[Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Exercise therapy in patients with peripheral arterial disease: the costs and effectiveness of physiotherapeutic supervision with or without therapy feedback versus a 'go home and walk' advice]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Exercise therapy for patellofemoral pain syndrome: a randomised clinical trial in general practice and sports medicine]
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Exercise therapy (Krankengymnastik / Heilgymnastik) in physical medicine]
2007	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exenatide in diabetes mellitus type 2 - Rapid report]
2020	National Committee for Technology Incorporation (CONITEC)	[Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Exantia® tissue bulking agent for the treatment of fecal incontinence]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target population]
2010	Basque Office for Health Technology Assessment (OSTEBA)	[Examination of barriers and facilitators for the implementation of clinical practice guidelines: a Delphi study]
2012	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Examination and treatment of older people after a fall – a health technology assessment]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evolocumab - Benefit assessment according to §35a Social Code Book V]